Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219940 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
A Phase 1 study of Healthy Subjects and Targeted Therapy, sponsored by Shine-On Biomedical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07219940 is a Phase 1 study of Healthy Subjects and Targeted Therapy that is actively recruiting participants, run by Shine-On Biomedical Co.. The registered enrollment target is 15 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07219940, a Phase 1 study of Healthy Subjects and Targeted Therapy, is actively recruiting participants, sponsored by Shine-On Biomedical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
Conditions Studied
Interventions
- DRUG SOB100
Study Locations (1)
Maryland
- Parexel International - Baltimore Early Phase Clinical Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07219940
The ClinicalTrials.gov registry entry for NCT07219940 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (88% lower). The listed sponsor is Shine-On Biomedical Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy Subjects appearing as the primary indexed condition, and to 1 intervention - of which SOB100 is the first listed.
NCT07219940 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT07219940 about?
NCT07219940 is a clinical study titled "A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects". The investigational drug, SOB100, is an HLA-G targeted exosome equipped with a nanobody namely anti-HLA-G VHH on the exosome membrane. This is a Phase I dose escalation study to exam the tolerability, safety, and pharmacokinetics in healthy subjects.
What is the current status of trial NCT07219940?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-12-01. Estimated completion is 2027-03.
What conditions does trial NCT07219940 study?
This clinical trial studies the following conditions: Healthy Subjects, Targeted Therapy, Exosome.
What interventions are being tested in trial NCT07219940?
The interventions under investigation include: SOB100 (DRUG).
Who is sponsoring clinical trial NCT07219940?
This trial is sponsored by Shine-On Biomedical Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219940 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
-
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.